研究

干细胞研究人员 干细胞研究人员

妙佑医疗国际的医生们在研究干细胞创新以改善护理。

神奇的干细胞

干细胞为检测和治疗带来了新的可能性。

单击此处信息图以了解更多信息

妙佑医疗国际的科学家使骨髓移植更加安全,并且改善患者的生活。他们对与移植有关的许多方面进行实验研究、临床试验和其他研究。妙佑医疗国际加入了血液和骨髓移植临床试验网络。妙佑的科学家经常与国内外的同事合作,分享自己的见解,以改善各地患者的护理。最近的研究包括:

  • 慢性移植物抗宿主病。由于长期从事骨髓移植,妙佑的研究人员有能力研究严重并发症(例如慢性移植物抗宿主病 (GVHD))的长期影响,以及如何治疗这些并发症。
  • 干细胞移植过程中的心律问题。心律问题(心律失常)通常是干细胞移植过程中的并发症。妙佑的研究人员对 983 名接受了干细胞移植的患者展开了研究,以更好地了解谁更有可能经历此问题。
  • 太空中的干细胞。妙佑医疗国际的研究人员已经向国际空间站发送了实验,以测试干细胞在微重力下是否生长得更好。
  • 针对移植物抗宿主病 (GVHD) 的成人(脂肪来源)干细胞。妙佑医疗国际的人类细胞治疗专家正在研究如何使用从脂肪或基质提取的干细胞(间充质干细胞)来抑制免疫和增强对移植物抗宿主病的组织修复。

阅读更多由妙佑医疗国际移植研究中心妙佑医疗国际癌症中心支持的骨髓移植研究。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际作者的文献列表

Research Profiles

Dec. 04, 2020
  1. National Marrow Donor Program. http://bethematch.org. Accessed Feb. 26, 2015.
  2. AskMayoExpert. Hematopoietic stem cell transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  3. AskMayoExpert. Graft-versus-host disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  4. Barbara Woodward Lips Patient Education Center. Allogeneic blood and marrow transplant (BMT). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2010.
  5. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. July 20, 2016.
  6. Lee SJ, et al. 5 year results of bmt ctn 0201: Unrelated donor bone marrow is associated with better psychological well-being and less burdensome chronic gvhd symptoms than peripheral blood. American Society of Hematology. Meeting abstract. https://ash.confex.com/ash/2015/webprogram/Paper80881.html. Accessed July 19, 2016.
  7. Adams RH (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 15, 2016.
  8. Geerdes PA (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 17, 2012.
  9. Reunited and it feels pretty good. In the Loop. July 28, 2015. http://intheloop.mayoclinic.org. Accessed July 19, 2016.
  10. Singla A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation. 2013;19:1233.
  11. Hoffman R, et al. Overview of hematopoietic stem cell transplantation. In: Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed July 19, 2016.
  12. Dispenzieri A. POEMS syndrome: 2012 update on diagnosis, risk-stratification and management. American Journal of Hematology. 2012;87:804.
  13. Yang ZZ, et al. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: Activation, suppression and exhaustion. Leukemia and Lymphoma. 2015;56:2498.
  14. Diseases treatable by transplants. National Marrow Donor Program. https://bethematch.org/transplant-basics/how-transplants-work/diseases-treatable-by-transplants/. Accessed July 20, 2016.
  15. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2012;18:348.
  16. Yawn BP, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033.
  17. NCCN member institutions. National Comprehensive Cancer Network. https://www.nccn.org. Accessed July 20, 2016.
  18. Cordes S, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis. 2016;27:101.
  19. Colborn LK. Office of Access Management. Mayo Clinic, Rochester, Minn. Jan. 28, 2016.
  20. Gertz MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clinic Proceedings. 2008;83:1131.
  21. O'Suoji C, et al. Rare pediatric non-Hodgkin lymphomas: A report from Children's Oncology Group Study ANHL 04B1. Pediatric Blood Cancer. 2016;63:794.
  22. Galardy PJ, et al. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: Therapeutic horizons. British Journal of Haematology. 2016;173:625.
  23. Slack JL, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: Outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biology of Blood and Marrow Transplantation. 2013;19:1167.
  24. King AA, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. American Journal of Hematology. 2015;90:1093.
  25. Mayo Clinic to grow human cells in space: Testing stroke treatment. Mayo Clinic News Network. http://newsnetwork.mayoclinic.org. Accessed July 20, 2016.
  26. Muchtar E, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. In press.
  27. Ansell SM. Targeting immune checkpoints in lymphoma. Current Opinion in Hematology. 2015;22:337.
  28. Hashmi S, et al. Survival aster mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis. The Lancet Haematology. 2016;1:e45-52. https://www.clinicalkey.com. Accessed July 20, 2016.